WITHDRAWN: Steroids for treating tuberculous meningitis

Cochrane Database Syst Rev. 2007 Jul 18:(1):CD002244. doi: 10.1002/14651858.CD002244.pub2.

Abstract

Background: Even though corticosteroids have been used alongside antituberculosis drugs for tuberculous meningitis (TBM) since the 1950s their role remains controversial. Some believe corticosteroids improve outcome while others point to the lack of supportive evidence. In patients who are immunocompromised because of HIV infection the risks and benefits of steroids are unknown.

Objectives: To assess the effects of steroids on death and disability in patients with TBM.

Search strategy: We searched the Cochrane Infectious Diseases Group specialized trials register (February 2005), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2005), MEDLINE (1966 to February 2005), EMBASE (1980 to February 2005), and LILACS (February 2005).

Selection criteria: Randomised controlled trials of steroids in people on TB treatment for TBM.

Data collection and analysis: Two independent reviewers applied study selection criteria, assessed methodological quality and extracted data.

Main results: Six trials of 595 patients met the inclusion criteria. No study described allocation concealment. Steroids were associated with fewer deaths (relative risk [RR] 0.79; 95% confidence interval [CI] 0.65 to 0.97) and a reduced incidence of death and severe residual disability (RR 0.58, 95% CI 0.38 to 0.88). Subgroup analysis suggests an effect on mortality in children (RR 0.77, 95% CI 0.62 to 0.96) but the results in a smaller number of adults are inconclusive (RR 0.96, 95% CI 0.50 to 1.84). There is little evidence that the severity of disease influences the effects of steroids on mortality.

Authors' conclusions: Adjunctive steroids might be of benefit in patients with TBM. However, existing studies are small, and poor allocation concealment and publication bias may account for the positive results found in this review. No data are available on the use of steroids in HIV positive persons. Future placebo-controlled studies should include patients with HIV infection and should be large enough to assess both mortality and disability.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use
  • Chemotherapy, Adjuvant
  • Child
  • Dexamethasone / therapeutic use
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use*
  • Humans
  • Hydrocortisone / therapeutic use
  • Prednisolone / therapeutic use
  • Randomized Controlled Trials as Topic
  • Tuberculosis, Meningeal / drug therapy*
  • Tuberculosis, Meningeal / mortality

Substances

  • Antitubercular Agents
  • Glucocorticoids
  • Dexamethasone
  • Prednisolone
  • Hydrocortisone